Merck Likes Biosimilars, But Not ESAs
This article was originally published in The Pink Sheet Daily
Executive Summary
Given cardiovascular risks associated with erythropoiesis-stimulating agents, Merck BioVentures is dropping a biosimilar based on Amgen's Aranesp.